arrow
R

Rajiv Jalan

Royal Free Hospital
H指数:99
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis

YAQ001对肝硬化患者肠道微生物组、通透性及全身炎症标志物的影响

2026-10-280
OAAI
Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver disease

α2A肾上腺素能受体拮抗剂可减少慢性肝病模型中的纤维化、炎症和门静脉高压

2026-09-010
PRE
Consensus versus Outcome-based Definitions of Acute-on-chronic Liver Failure: Implications for Risk Stratification and Case Identification

共识与基于结局的定义在急性-on-慢性肝衰竭中的应用:对风险分层和病例识别的影响

2026-05-010
OA
Patient Plasma-Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis

患者血浆诱导的中性粒细胞功能障碍与肝硬化急性失代偿患者的感染风险和死亡率相关。

2025-12-011
OA
Soluble Urokinase Plasminogen Activator Receptor is a prognostic biomarker in decompensated liver cirrhosis

可溶性尿激酶型纤溶酶原激活剂受体是失代偿期肝硬化的预后生物标志物

2025-11-110
OAAI
Corrigendum to “Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis” [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028]

勘误:“非急性肝硬变失代偿的临床和病理生理特征” [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028]

2025-09-250
PRE
Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis

RIPK3作为预测急性失代偿期肝硬化患者预后的新型生物标志物的鉴定与验证

2025-08-120
PRE
Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ
2024-11-131
OAAI